(Q30385089)

21 June 2017

title

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. (English)

1 reference

21 June 2017

main subject

phase I clinical trial

0 references

influenza A virus

object named as

influenza A virus

1 reference

14

Robert B Belshe

1 reference

21 June 2017

Larry R Smith

1

1 reference

21 June 2017

Mary K Wloch

2

1 reference

21 June 2017

Ming Ye

3

1 reference

21 June 2017

Luane R Reyes

4

1 reference

21 June 2017

Souphaphone Boutsaboualoy

5

1 reference

21 June 2017

Casey E Dunne

6

1 reference

21 June 2017

Jennifer A Chaplin

7

1 reference

21 June 2017

Denis Rusalov

8

1 reference

21 June 2017

Alain P Rolland

9

1 reference

21 June 2017

Cindy L Fisher

10

1 reference

21 June 2017

Mohamed S Al-Ibrahim

11

1 reference

21 June 2017

Martin L Kabongo

12

1 reference

21 June 2017

Roy Steigbigel

13

1 reference

21 June 2017

Ernest R Kitt

15

1 reference

21 June 2017

Alice H Chu

16

1 reference

21 June 2017

Ronald B Moss

17

1 reference

21 June 2017

language of work or name

English

0 references

publication date

29 January 2010

1 reference

21 June 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

28

1 reference

21 June 2017

issue

13

1 reference

21 June 2017

page(s)

2565-2572

1 reference

Update on avian influenza A (H5N1) virus infection in humans

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Implications of the emergence of a novel H1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

The annual production cycle for influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.029

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.01.029

1 reference

21 June 2017

1 reference